找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Biopharmaceutical Applied Statistics Symposium; Volume 3 Pharmaceuti Karl E. Peace,Ding-Geng Chen,Sandeep Menon Book 2018 Springer Nature S

[復制鏈接]
樓主: Ingrown-Toenail
61#
發(fā)表于 2025-4-1 02:38:54 | 只看該作者
Interesting Applications from Three Decades of Biostatistical Consulting,d later dose discrimination, as well as illustrating the need to carefully define the trial objective. The last example provides an overview of assessing whether evidence exists from two Phase II trials of angina to support conducting a Phase III trial at either a b.i.d. or t.i.d. drug.
62#
發(fā)表于 2025-4-1 09:01:02 | 只看該作者
Overview of Omics Biomarker Discovery and Design Considerations for Biomarker-Informed Clinical Trih-throughput omics technologies has enabled scientists to discover new biomarkers with low cost. Leveraging available technology and biomarker information, novel biomarker-based clinical trial designs have been proposed and have proven beneficial to many clinical programs. In this chapter, we discus
63#
發(fā)表于 2025-4-1 10:43:54 | 只看該作者
Phase 3 Oncology Trials of Personalized Medicines with Adaptive Subpopulation Selection,ever, there is great uncertainty about drug activity in a subpopulation when designing a confirmatory trial in practice and it is logical to take a two-stage adaptive approach. The first stage de-selects (or prunes) non-performing subpopulations at an interim analysis, and the second stage pools the
64#
發(fā)表于 2025-4-1 17:19:47 | 只看該作者
,Synergy or Additivity—The Importance of Defining the Primary Endpoint and the Approach to Its Statio therapeutic agents depends to a critical degree on how “synergy” is defined and how the data are analyzed. To illustrate these points, a hypothetical example based on an actual case is discussed. In the example, a common set of clinical trials was analyzed by two different organizations with two d
65#
發(fā)表于 2025-4-1 19:27:13 | 只看該作者
Recycling of Significance Levels in Testing Multiple Hypotheses of Confirmatory Clinical Trials, types and sometimes into other lower types. The primary hypotheses enjoy a special status; if the trial wins for one or more primary hypotheses, then one can characterize clinically relevant benefits of the study treatment. This framework of classifying hypotheses based on their importance into pri
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學 Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學 Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-17 08:47
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復 返回頂部 返回列表
芦山县| 昌黎县| 高平市| 防城港市| 图们市| 甘泉县| 申扎县| 金门县| 清水县| 金华市| 江安县| 平遥县| 青州市| 左贡县| 宿州市| 洞口县| 连南| 淮安市| 古丈县| 江城| 山阴县| 扎赉特旗| 沁阳市| 浦江县| 昂仁县| 集贤县| 望江县| 宜丰县| 泸溪县| 忻城县| 乡城县| 岳西县| 临武县| 邻水| 中山市| 阿克陶县| 成都市| 武乡县| 阿拉善左旗| 阜城县| 阿克苏市|